113997-58-3

Basic information

• Product Name: (R)-1-(1H-indol-3-yl)-N-((R)-1-phenylethyl)propan-2-amine
• Synonyms: (R)-1-(1H-indol-3-yl)-N-((R)-1-phenylethyl)propan-2-amine
• CAS NO: 113997-58-3
• Molecular Weight: 278.397
• Mol File: 113997-58-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-1-(1H-indol-3-yl)-N-((R)-1-phenylethyl)propan-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(1H-indol-3-yl)-N-((R)-1-phenylethyl)propan-2-amine(113997-58-3)
• EPA Substance Registry System: (R)-1-(1H-indol-3-yl)-N-((R)-1-phenylethyl)propan-2-amine(113997-58-3)

Safety Data

• Hazardous Substances Data: 113997-58-3(Hazardous Substances Data)

Upstream product

• 1201-26-9 3-(1H-indolyl)acetone 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 4771-72-6 α-methyl-β-(3-indolyl)-1-nitroethane 

Downstream Products

• 7795-52-0 (-)-alpha-Methyltryptamine 

Relevant articles and documents

REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS

Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. The antagonists (such as a hexahydro pyrido[3,4-b]indole, AZD9496, RAD-1901, ARN-810, endoxifen, or fulvestrant) may be an inhibitor of both activating function 1 and activating function 2 of the estrogen receptor. Also provided are combinations of above inhibitors with a secondary agent, which is a CDK 4/6 inhibitor (such as, palbocociclib, ribociclib, abemaciclib, lerociclib, and trilaciclib).

TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS

The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.